Chorea

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

Retrieved on: 
Monday, February 26, 2024
FDA, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Tardive dyskinesia, Chorea, VMAT2, Metabolism, EVP, Deuterium, Annual report, TEVA, Marketing, Teva, Partnership, HD, Quality of life, Food, Schizophrenia, Neurological disorder, DSM-IV codes, Globalization, Neuro, Prevalence, Happy Mood, Face, Anesthesia, Central nervous system disease, Pivot, Tongue, CNS, Psychiatry, Patient, Pain, Disease, Extremities, Research, Pharmaceutical industry

The partnership intends to increase patients’ access to Teva’s AUSTEDO, leveraging Nhwa’s leadership in China’s neuro-psychiatric health sector.

Key Points: 
  • The partnership intends to increase patients’ access to Teva’s AUSTEDO, leveraging Nhwa’s leadership in China’s neuro-psychiatric health sector.
  • “Nhwa has deep neuro-psychiatry expertise and capabilities, from research and development to commercialization,” commented Theodor Wee, General Manager of Teva Greater China.
  • Chorea, one of the most striking physical manifestations of Huntington’s disease, is a neurological disorder that causes involuntary, random muscle movements.
  • Jiangsu Nhwa Pharmaceutical Co., Ltd., founded in 1978, is a leading CNS company in China.

US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority

Retrieved on: 
Wednesday, January 3, 2024
Movement, Family, Caudate nucleus, PTC, SOM, Disease, Chorea, Frustration, Brain, Research, HD, Therapy, Tardive dyskinesia, Neurology, Dementia, Huntingtin, Atrophy, Pathology, PTC Therapeutics, Optimism, Patient, Movement disorder, Neuron, Pharmaceutical industry

Thus, often without full awareness, patients lose motor control, experience psychiatric symptoms, and cognitive decline.

Key Points: 
  • Thus, often without full awareness, patients lose motor control, experience psychiatric symptoms, and cognitive decline.
  • A neurologist’s perspective from a recent research study suggests:
    “A Huntington’s patient is almost a combination of Alzheimer’s, tardive dyskinesia, Parkinson’s - all in one.
  • Recognizing the significant treatment unmet needs, Spherix Global Insights conducted a market landscape study, seeking insights from neurologists managing HD.
  • Additionally and unaided, neurologists also mentioned Annexon Biosciences’ ANX005, Azevan Pharmaceuticals’ SRX246, SOM Biotech’s SOM3355, and Vaccinex, Inc.’s pepinemab.

Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023

Retrieved on: 
Thursday, November 2, 2023
Week, Falls, Food, Fatigue, HD, Treatment, Neurocrine, Disease, Neurocrine Biosciences, Maintenance, Journal, Somnolence, Poster, Abstract, Huntington's disease, Interim, Capsule, George Huntington, HSG, Food and Drug Administration, SAN, Dietary supplement, Pharmaceutical industry, Chorea

Interim data suggest one-capsule, once-daily INGREZZA improved chorea at the first evaluation at Week 2 with sustained efficacy through Week 50.

Key Points: 
  • Interim data suggest one-capsule, once-daily INGREZZA improved chorea at the first evaluation at Week 2 with sustained efficacy through Week 50.
  • These data will be presented at the 30th Annual Meeting of the Huntington Study Group on November 2–4 in Phoenix.
  • "These interim data provide insight on the clinically meaningful and sustained improvements participants are experiencing with INGREZZA for the treatment of chorea," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences®.
  • Additional HD chorea presentations at the 30th Annual Meeting of the HSG include:
    The full abstracts can be accessed on the Journal of Huntington's Disease website.

Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023

Retrieved on: 
Wednesday, September 6, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Teva Pharmaceuticals, HD, Abstract (summary), LAI, Risk, Different Stages, TEVA, Global R&D management, Olanzapine, Teva, De novo, TD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lais, Doctor of Philosophy, Medication, Depression, Risperidone, Poster, Migraine, MD, Treatment, TASE, Post hoc analysis, Chorea, Reactions on surfaces, FDA, Mental health, NYSE, Tardive dyskinesia, Food, Pharmaceutical industry, Patient, Schizophrenia

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 16 data presentations across its neuroscience portfolio happening at Psych Congress on September 6-10 in Nashville, TN.

Key Points: 
  • Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 16 data presentations across its neuroscience portfolio happening at Psych Congress on September 6-10 in Nashville, TN.
  • Abstracts include data for AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 and AJOVY.
  • Once-daily AUSTEDO XR, a new formulation of twice-daily AUSTEDO was approved by the U.S. Food and Drug administration (FDA) in February 2023 for adults with TD and chorea associated with Huntington’s disease (HD), and UZEDY, a long-acting formulation of risperidone for subcutaneous use, was approved by the FDA in April 2023 for adults with schizophrenia.1,2 TV-44749 is an investigational formulation of olanzapine currently being studied in adults with schizophrenia.3
    “Because of the immense impact that mental health and neurological conditions like schizophrenia, TD and HD pose for patients, we are constantly striving to advance research that can enhance available treatment options,” said Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer at Teva.
  • “Following this year’s FDA approval of once-daily AUSTEDO XR and UZEDY and the excitement they have received from the medical community, we are thrilled to continue to share research showcasing their potential for patients living with these debilitating conditions.”
    In addition to these data presentations, Teva will also be hosting a symposium to discuss results of the DECIDE study, highlighting perspectives from U.S. psychiatric clinicians on selecting and initiating LAI antipsychotics as well as the real-world barriers that cause LAIs to remain underutilized in clinical practice.

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

Retrieved on: 
Monday, August 28, 2023
Huntington's disease, Pit additive, KINECT, Lancet Neurology, Week, Disease, McGovern Medical School, Neurocrine Biosciences, Clinical Global Impression, Movement disorder, The Lancet, MDS, Capsule, Movement, TMC, SAN, Chorea, Parkinson's disease, FANA, Neurology, Poster, FAAN, FDA, Safety, Pharmaceutical industry, HD

SAN DIEGO, Aug. 28, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA® (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD), including exploratory results from the Phase 3 KINECT®-HD study, which showed consistently greater improvements in HD chorea with INGREZZA versus placebo from Week 2 to Week 12. These data will be presented at the MDS International Congress of Parkinson's Disease and Movement Disorders®August 27-31 in Copenhagen, Denmark.

Key Points: 
  • These data will be presented at the MDS International Congress of Parkinson's Disease and Movement Disorders®August 27-31 in Copenhagen, Denmark.
  • "The exploratory analysis from our KINECT-HD study further exemplifies the value of INGREZZA as a now approved medication for HD chorea with improvements seen with treatment as early as two weeks," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences.
  • "This exploratory analysis has increased our insight regarding the early and sustained improvements in chorea severity."
  • Additional HD chorea presentations at the MDS International Congress of Parkinson's Disease and Movement Disorders include:

Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease

Retrieved on: 
Friday, August 18, 2023
Huntington's disease, Maintenance, VMAT2, Chorea, Depression, Pharmacy, Somnolence, Disease, Huntington's Disease Society of America, Neurocrine Biosciences, Quality of life, Medicine, NMS, Hives, Behavior, Rash, HSG, Insomnia, Capsule, LSM, TMC, Patient, McGovern Medical School, Neuroleptic malignant syndrome, SAN, FANA, Suicidal ideation, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FAAN, Food, Caregiver, Safety, Pharmaceutical industry, Birth control, HD, Neurology

"We are thankful for those in the HD community who helped contribute to this important milestone, and we remain committed to bringing medicines to patients with unmet medical needs for debilitating neurological disorders."

Key Points: 
  • "We are thankful for those in the HD community who helped contribute to this important milestone, and we remain committed to bringing medicines to patients with unmet medical needs for debilitating neurological disorders."
  • In clinical studies in Huntington's disease, treatment-emergent adverse events included somnolence and sedation, urticaria, rash and insomnia.
  • "Data also demonstrated INGREZZA was generally well tolerated and showed clinically meaningful improvement in adults with chorea associated with HD."
  • "The approval of INGREZZA for HD chorea means that people living with HD have a new treatment option to help manage their chorea symptoms, which is a welcomed milestone in efforts to improve care for families affected by HD."

SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.

Retrieved on: 
Tuesday, August 1, 2023
Patent, Extremities, CSE, Central nervous system, Therapy, Tic disorder, Face, United States Patent and Trademark Office, DSM-IV codes, Tourette syndrome, Dystonia, FSE, IP, TEL, Disorder, Parkinson's disease, CWY, Chorea, Pharmaceutical industry, Dyskinesia

The provisional patent application was filed with the United States Patent and Trademark Office.

Key Points: 
  • The provisional patent application was filed with the United States Patent and Trademark Office.
  • This patent application refers to combination of the psychedelic molecule 3-Methylmethcathinone, known as 3-MMC, and SciSparc's Palmitoylethanolamide as a potential treatment for dyskinesia.
  • This patent prospect corresponds well with SciSparc’s robust IP portfolio and some of the indications the Company is already pursuing such as Tourette Syndrome.
  • Our collaboration with Clearmind continues to bear fruit and emphasizes our commitment to pioneering innovative treatments for conditions with unmet need,” stated SciSparc’s Chief Executive Officer, Oz Adler.

Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio

Retrieved on: 
Tuesday, August 1, 2023
Patent, Extremities, CSE, Obesity, Therapy, Face, United States Patent and Trademark Office, DSM-IV codes, MEAI, Dystonia, FSE, Disorder, Parkinson's disease, Patient, CWY, Myenteric plexus, Chorea, Pharmaceutical industry, Dyskinesia

The patent application refers to the psychedelic molecule 3-Methylmethcathinone ("3-MMC”) as a potential treatment for Dyskinesia thus expanding Clearmind’s IP portfolio for innovative molecules, new indications and treatments.

Key Points: 
  • The patent application refers to the psychedelic molecule 3-Methylmethcathinone ("3-MMC”) as a potential treatment for Dyskinesia thus expanding Clearmind’s IP portfolio for innovative molecules, new indications and treatments.
  • "Clearmind continues to strengthen its position as a leader in the psychedelic-derived therapeutics industry through an aggressive strategy to expand our IP portfolio.
  • Clearmind has a broad IP footprint in the psychedelic space with 30 patents and patent applications across 14 patent families, nine of which have been granted in major jurisdictions like the US, Europe, China, and India.
  • The company has already filed patent applications for the combination of Clearmind's MEAI with SciSparc's Palmitoylethanolamide for treating alcohol use disorder, cocaine addiction, and obesity, as well as related metabolic disorders.

Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023

Retrieved on: 
Friday, June 2, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Psych, Teva Pharmaceuticals, Interim, Risk, VMAT2, TEVA, Global R&D management, START, Teva, Use, TD, De novo, State University of New York Upstate Medical University, Safety, Efficacy, Clinical Global Impression, Doctor of Philosophy, Patient, Medication, PGIC, Tablet, Congress, DE, User experience, MD, Poster, Randomness, TASE, Olanzapine, Annual general meeting, Chorea, Treatment, AM, Effectiveness, Reactions on surfaces, XR, FDA, Mental health, Tardive dyskinesia, NYSE, SHINE, Pharmaceutical industry, Nursing, Tolerability, Schizophrenia

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 12 presentations across its neuroscience portfolio featured at the Psych Congress Elevate 2023 Annual Meeting taking place on June 1-4, 2023.

Key Points: 
  • Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 12 presentations across its neuroscience portfolio featured at the Psych Congress Elevate 2023 Annual Meeting taking place on June 1-4, 2023.
  • Two presentations feature real-world data for AUSTEDO (deutetrabenazine) tablets for adults living with TD.
  • Data presented will include interim findings from the START trial, a Phase 4 study investigating real-world utilization of AUSTEDO with a 4-week patient titration kit along with treatment success as measured at the end of treatment.
  • Teva will also present findings from studies evaluating potential drug-drug interactions with VMAT2 inhibitors, as well as patient and healthcare provider perspectives on the impact of TD.

Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology

Retrieved on: 
Friday, May 19, 2023
Huntington's disease, Neuron, VMAT2, KINECT, Akathisia, Somnolence, Week, Disease, McGovern Medical School, New Drug Application, Heredity, Neurocrine Biosciences, Brain, Department of Neurology, Xuanwu hospital, Fatigue, HSG, DSM-IV codes, Shanda, TMC, Suicide, Patient, Manuscript, SAN, Memorial Hermann Health System, Chorea, Quality of life, PDUFA, Neurology, Suicidal ideation, FDA, Lancet, The Lancet, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, Propane, Medical imaging, HD, Valbenazine

SAN DIEGO, May 19, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that the complete study results from its Phase 3 KINECT™-HD study investigating valbenazine for the treatment of chorea associated with Huntington's disease (HD) has been published in The Lancet Neurology online edition and will appear in the June 2023 print issue. The study met pre-defined primary and secondary endpoints of improvement in chorea severity and global impression of change, demonstrating a reduction in chorea symptoms associated with HD and improvement of overall chorea severity as noticed by clinicians and patients, with improvement seen as early as Week 2 of the initial dose in the 12-week study.

Key Points: 
  • "The KINECT-HD study data demonstrated statistically significant improvement in chorea associated with HD as compared with placebo.
  • The safety profile for participants with chorea associated with HD was consistent with the known safety profile of valbenazine.
  • The KINECT-HD study marked the first-ever implementation of the Huntington's Disease Health Index (HD-HI) in a Phase 3 trial.
  • The filing included data from the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label study of valbenazine in adults with chorea associated with HD.